Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Clinical Investigations Compliance & Enforcement

Clinical Investigations Compliance & Enforcement Home
          Science & Research
          Science and Research Special Topics
          Clinical Trials and Human Subject Protection
          Clinical Investigations Compliance & Enforcement
          Institutional Review Boards – Restrictions Imposed Letters and Disqualification ProceedingsClinical Investigations Compliance & Enforcement Institutional Review Boards – Restrictions Imposed Letters and Disqualification Proceedings
  
  	
    Share
    Post
    Linkedin

    Email
    PrintInstitutional Review Boards (IRBs) review clinical investigations regulated by the Food and Drug Administration (FDA) under sections 505(i) and 520(g) of the Federal Food, Drug, and Cosmetic Act, as well as clinical investigations that support applications for research or marketing permits for products regulated by the FDA. FDA’s regulations in 21 CFR parts 50 and 56 set forth certain requirements for IRBs regarding their oversight of those clinical investigations. An IRB’s compliance with the regulations is intended to protect the rights and welfare of human subjects involved in such investigations.

**Restrictions Letter**. When, during an inspection, FDA has observed apparent noncompliance by an IRB with the applicable regulations, FDA may notify the IRB and the parent institution in writing of the noncompliance (e.g., Warning Letter, Restrictions Letter) and require that the IRB or parent institution respond to the letter within a time period specified by FDA and describe the corrective actions that will be taken by the IRB, the institution, or both to achieve compliance with the regulations. (21 CFR 56.120(a)) In addition, until the IRB or institution takes appropriate corrective action, FDA may impose restrictions on the IRB. (21 CFR 56.120(b)) An Institutional Review Board – Restrictions Imposed Letter (Restrictions Letter) is a noncompliance letter issued under 21 CFR 56.120(a) that imposes such restrictions on the IRB. See 21 CFR 56.103, 56.110(d), and 56.120(b).

Based on information provided by the IRB or institution, FDA may remove the restrictions imposed in the Restrictions Letter.

Whenever the IRB or the institution has failed to take adequate steps to correct the noncompliance stated in the letter sent by the agency under 21 CFR 56.120(a), and the Commissioner determines that this noncompliance may justify the disqualification of the IRB or the parent institution, the Commissioner will institute disqualification proceedings in accordance with the requirements for a regulatory hearing set forth in 21 CFR part 16. (21 CFR 56.121(a))

**Notice of Opportunity for Hearing (NOOH).**The NOOH provides the IRB with the opportunity for a regulatory hearing on the proposed disqualification action before a presiding officer designated by the Commissioner, as described in 21 CFR part 16. The IRB or institution may request a hearing or decline the opportunity for a hearing. In declining the hearing, the IRB or institution may request in writing that the agency make a determination based on the available information.

Disqualification of an IRB. The Commissioner may disqualify an IRB or the parent institution if the Commissioner determines, per 21 CFR 56.121(b), that:

The IRB has refused or repeatedly failed to comply with any of the applicable regulations, and
	The noncompliance adversely affects the rights or welfare of the human subjects in a clinical investigation.If the Commissioner determines that disqualification is appropriate, the Commissioner will issue an order that explains the basis for the determination and that prescribes any actions to be taken with regard to ongoing clinical research conducted under the review of the IRB. FDA will send notice of the disqualification to the IRB and the parent institution. (21 CFR 56.121(c))

The table below lists the dates that actions were taken by the FDA for each IRB listed. Clicking on these dates will allow the user to view the regulatory correspondence issued to the IRB by the FDA. To search for previously posted letters in which FDA has imposed restrictions in accordance with 21 CFR 56.103 and 56.120(b), see the Warning Letters webpage.

IRB Name
			Status & Date
			Restrictions Imposed
			Restrictions Removed
			NOOH
			Presiding Officer's Report
			Commissioner's Decision
			Disqualification OrderAdvanced Magnetic Research Institute
			Restricted 07/10/2017
			07/10/2017
			N/A
			N/A
			N/A
			N/A
			N/AAmerican Association of Acupuncture and Bio-Energetic Medicine (AAABEM)
			c/o Institute of Bio-Energetic Medicine
			Restricted 11/14/2013
			11/14/2013
			N/A
			N/A
			N/A
			N/A
			N/ABurzynski Research Institute – Institutional Review Board (BRI IRB)
			Restrictions removed 04/11/2014
			09/23/2013
			04/11/2014
			N/A
			N/A
			N/A
			N/AInland Institute of Aesthetic Dentistry IRB
			Restricted 05/13/2015
			05/13/2015
			N/A
			N/A
			N/A
			N/A
			N/ATexas Applied Biomedical Services (TABS) Research Review Committee (RRC) IRB
			Disqualified 02/29/2016
			09/25/2012
			(Issued as a Warning Letter)
			N/A
			09/16/2014
			N/A
			02/29/2016
			02/29/2016



Additional Resources

21 CFR 56
	21 CFR part 16

                                                                                  Content current as of:
      06/19/2020Clinical Investigations Compliance & Enforcement
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop